Literature DB >> 21871560

Redox regulation of human protease-activated receptor-2 by activated factor X.

Klaus Jobi1, Bernhard H Rauch, Seema Dangwal, Kerstin Freidel, Anke Doller, Wolfgang Eberhardt, Jens W Fischer, Karsten Schrör, Anke C Rosenkranz.   

Abstract

Activated factor X (FXa) exerts coagulation-independent actions such as proliferation of vascular smooth muscle cells (SMCs) through the protease-activated receptors PAR-1 and PAR-2. Both receptors are upregulated upon vascular injury but the underlying mechanisms have not been defined. We examined if FXa regulates PAR-1 and PAR-2 in human vascular SMCs. FXa increased PAR-2 mRNA, protein, and cell-surface expression and augmented PAR-2-mediated mitogenesis. PAR-1 was not influenced. The regulatory action of FXa on PAR-2 was concentration-dependent and mimicked by a PAR-2-selective activating peptide. PAR-2 regulation was not influenced by the thrombin inhibitor argatroban or PAR-1 siRNA. FXa increased dichlorofluorescein diacetate fluorescence and 8-isoprostane formation and induced expression of the NADPH oxidase subunit NOX-1. NOX-1 siRNA prevented FXa-stimulated PAR-2 regulation, as did ebselen and cell-permeative and impermeative forms of catalase. Exogenous H(2)O(2) increased PAR-2 expression and mitogenic activity. FXa promoted nuclear translocation and PAR-2/DNA binding of nuclear factor κB (NF-κB); NF-κB inhibition prevented PAR-2 regulation by FXa. FXa also promoted PAR-2 mRNA stabilization through increased human antigen R (HuR)/PAR-2 mRNA binding and cytoplasmic shuttling. HuR siRNA abolished FXa-stimulated PAR-2 expression. Thus FXa induces functional expression of PAR-2 but not of PAR-1 in human SMCs, independent of thrombin formation, via a mechanism involving NOX-1-containing NADPH oxidase, H(2)O(2), NF-κB, and HuR.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871560     DOI: 10.1016/j.freeradbiomed.2011.08.003

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  8 in total

1.  FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.

Authors:  Guillermo Moñux; Jose J Zamorano-León; Pablo Marqués; Bernardo Sopeña; J M García-García; G Laich de Koller; Bibiana Calvo-Rico; Miguel A García-Fernandez; J Serrano; Antonio López-Farré
Journal:  Br J Clin Pharmacol       Date:  2017-08-27       Impact factor: 4.335

2.  Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients.

Authors:  Antonio J López-Farré; Pablo Rodriguez-Sierra; Javier Modrego; Antonio Segura; Naiara Martín-Palacios; Ana M Saiz; José J Zamorano-León; Juan Duarte; Javier Serrano; Guillermo Moñux
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 3.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

4.  Factor Xa induces pro-inflammatory cytokine expression in RAW 264.7 macrophages via protease-activated receptor-2 activation.

Authors:  Pengfei Zuo; Zhi Zuo; Xin Wang; Long Chen; Yueyue Zheng; Genshan Ma; Qianxing Zhou
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

5.  Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis.

Authors:  Corey S Moran; Sai-Wang Seto; Smriti M Krishna; Surabhi Sharma; Roby J Jose; Erik Biros; Yutang Wang; Susan K Morton; Jonathan Golledge
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

Review 6.  Reactive Oxygen Species in Venous Thrombosis.

Authors:  Clemens Gutmann; Richard Siow; Adam M Gwozdz; Prakash Saha; Alberto Smith
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

7.  Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5.

Authors:  Fumihiro Sanada; Yoshiaki Taniyama; Jun Muratsu; Rei Otsu; Masaaki Iwabayashi; Miguel Carracedo; Hiromi Rakugi; Ryuichi Morishita
Journal:  Sci Rep       Date:  2016-10-18       Impact factor: 4.379

Review 8.  Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.

Authors:  Hugo Ten Cate; Tomasz J Guzik; John Eikelboom; Henri M H Spronk
Journal:  Cardiovasc Res       Date:  2021-07-27       Impact factor: 10.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.